Skip to content
lifestyle.thenyctimes.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Holding(s) in Company
March 12, 2026
Update to Faron’s Financial Calendar and Date of the Annual General Meeting in 2026
March 9, 2026
CORRECTION: Faron Pharmaceuticals Ltd’s Annual Report 2025 published
March 4, 2026
Faron’s Financial Statements Release 1 January to 31 December 2025
March 4, 2026
Faron Pharmaceuticals Ltd’s Annual Report 2025 Published
March 4, 2026
Faron Pharmaceuticals Ltd: Results of the Extraordinary General Meeting
March 2, 2026
Faron and City of Hope in Process of Developing a Phase II Investigator-Initiated Trial of Bexmarilimab in Relapsed/Refractory MDS
March 2, 2026
Faron’s Bexmarilimab Data Accepted for Poster Presentation at the BSH Annual Scientific Meeting 2026
February 23, 2026
Faron Announces Phase II BEAM-X IIT Led by the Nordic AML Group Evaluating Bexmarilimab in Post-Transplant AML
February 19, 2026
Faron Pharmaceuticals Ltd: Notice To The Extraordinary General Meeting
February 12, 2026
←
Previous Page
1
2
3
4
Next Page
→